Other OTC - Delayed Quote USD

Inhibitor Therapeutics, Inc. (INTI)

0.1376 0.0000 (0.00%)
At close: May 13 at 9:30 AM EDT
Loading Chart for INTI
DELL
  • Previous Close 0.1376
  • Open 0.1376
  • Bid --
  • Ask --
  • Day's Range 0.1376 - 0.1376
  • 52 Week Range 0.0130 - 0.3000
  • Volume 3,571
  • Avg. Volume 10,040
  • Market Cap (intraday) 23.671M
  • Beta (5Y Monthly) -0.81
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0200
  • Earnings Date Aug 10, 2024 - Aug 14, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc is a subsidiary of Mayne Pharma Ventures Pty Ltd.

inhibitortx.com

3

Full Time Employees

December 31

Fiscal Year Ends

Recent News: INTI

Performance Overview: INTI

Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

INTI
49.57%
S&P 500
10.00%

1-Year Return

INTI
252.82%
S&P 500
27.22%

3-Year Return

INTI
83.47%
S&P 500
27.58%

5-Year Return

INTI
102.35%
S&P 500
86.59%

Compare To: INTI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: INTI

Valuation Measures

Annual
As of 5/13/2024
  • Market Cap

    23.67M

  • Enterprise Value

    12.13M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    4.48

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -20.34%

  • Return on Equity (ttm)

    -44.57%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -3.03M

  • Diluted EPS (ttm)

    -0.0200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.84M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -1.8M

Research Analysis: INTI

Company Insights: INTI

Research Reports: INTI

People Also Watch